Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent~2. Outpatient~3. Age (\>= 18 years at Visit 1 for Russia, Ukraine, and Germany; \>= 12 years at Visit 2 for all other countries)~4. Diagnosis of uncomplicated acute rhinosinusitis~5. Ability and willingness to comply with study procedures and restrictions.~6. Male or eligible female - Female subjects should not be enrolled if they plan to become pregnant during the time of study participation; To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control.~7. Literate~Exclusion Criteria:~1. Based on the investigator's clinical judgement, subject has fulminant bacterial rhinosinusitis during the screening period including Visits 1 and 2.~2. A history of acute rhinosinusitis within 12 weeks prior to the current episode as determined by the investigator~3. Current or a history of other sinonasal conditions (e.g., chronic or recurrent rhinosinusitis, non-allergic rhinitis) within 3 years prior to Visit 1 as determined by the investigator~4. Symptomatic perennial or seasonal allergic rhinitis prior to ARS episode, or allergy to seasonal allergens likely to be present during the study period (as determined by documented skin prick test or in vitro blood test).~5. Significant concomitant medical conditions~6. Subjects with planned elective surgery, vacation or other event during the study period which could prevent the subject from participating in the study according to protocol specifications~7. Use of antibiotics within 30 days prior to Visit 1 for sinopulmonary infections.~8. Use of antiviral medications such as zanamivir and oseltamivir within 30 days prior to Visit 1~9. Use of analgesics or antipyretics within 1 day prior to Visit 1~10. Known hypersensitivity or allergy to corticosteroids or any excipients in the product~11. Use of corticosteroids, defined as:~12. Use of any other medications that may affect nasal symptoms~13. Use of immunosuppressive medications eight weeks prior to screening and during the study~14. Immunotherapy~15. Use of any medications that significantly inhibit the cytochrome P450 subfamily enzyme CYP3A4, including ritonavir and ketoconazole~16. Clinical trial/experimental medication experience~17. Positive pregnancy test or inconclusive pregnancy test or female who is breastfeeding~18. Affiliation with investigational site~19. Current tobacco use~20. Chicken pox or measles

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FFNS 110 mcg QD (Type: EXPERIMENTAL): None
- FFNS 110 mcg BID (Type: EXPERIMENTAL): None
- Placebo Nasal Spray (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete